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Abstract 
A 47-year-old female patient with rheumatoid arthritis (RA) treated with methotrexate, was 
diagnosed with metastatic melanoma. After surgical removal of the tumor, the patient start-
ed treatment with ipilimumab while methotrexate was stopped. One week after initiation of 
ipilimumab, the patient developed typical symptoms of RA. Analgetic therapy was started. 
After 4 cycles of ipilimumab, melanoma progression was radiologically evident. The treat-
ment plan was changed to pembrolizumab (anti-PD1 antibody), and the patient did not show 
active signs of RA anymore. Despite treatment with pembrolizumab, the patient died 4 
months later due to tumor progression. The exact mechanism by which ipilimumab (anti-
CTLA-4 antibody) provoked RA symptoms is still not fully understood. This subject needs 
more investigation, especially in an era in which immunotherapies are a standard therapy for 
patients with malignancy. © 2017 The Author(s) 
 Published by S. Karger AG, Basel 
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Introduction  
Rheumatoid arthritis (RA) is a chronic, T-cell mediated autoimmune disease character-
ized by extensive synovitis, resulting in the destruction of joint cartilage and bone [1]. Al-
though the pathogenesis of RA remains poorly understood, the importance of the costimula-
tory molecules CD28 and CTLA-4 in the disease process has been demonstrated [2]. The 
worsening of RA in a patient treated with ipilimumab for metastatic melanoma has been 
previously described in the literature [3].  
Ipilimumab and pembrolizumab are both immunotherapeutic agents used for the 
treatment of metastatic melanoma. These agents act on 2 different immune checkpoint regu-
lators. Ipilimumab is a monoclonal antibody that blocks the cytotoxic T-lymphocyte-
associated antigen-4 (CTLA-4) on T cells and therefore enhances an antitumor immunity by 
activating T-lymphocyte proliferation. Pembrolizumab is a fully humanized monoclonal an-
tibody that inhibits the programmed death-1 receptor (PD-1) on T-cells resulting in an in-
creased tumor-specific immune response [4].  
In this report, we describe a case of a patient who experienced increased RA activity 
during ipilimumab treatment, but stable RA activity during pembrolizumab for metastatic 
melanoma.  
Case Report 
A 47-year-old woman with RA who was being treated with methotrexate, was diagnosed 
with a spitzoid melanoma in March 2004 and the tumor was surgically removed. In 2010, 
the RA treatment was changed to infliximab (Remicade). After almost 10 years of a tumor-
free period, the patient returned to our clinic in May 2013 with swollen left axillary lymph 
nodes. Nodal metastasis was confirmed after fine-needle aspiration. A PET scan showed 
pulmonary, liver, and subcutaneous metastasis as well. Infliximab was stopped and metas-
tasectomy of the left axilla was performed. Treatment with ipilimumab was started at  
3 mg/kg every 3 weeks for 4 cycles in an expanded access program in August 2013. One 
week following the first injection of ipilimumab, the patient developed classic symptoms of 
severe arthritis affecting both hands and feet as well as both knees. Clinically, the patient 
showed swelling and redness of all extremities. The right knee was painful but with good 
range of motion. Inflammatory markers were elevated with a C-reactive protein (CRP) of 35 
mg/L (N <5 mg/L) and no sign of leukocytosis. No radiological joint scan was performed  
at this point. An anti-inflammatory and analgesic therapy with a nonsteroidal anti-
inflammatory drug (ibuprofen) was prescribed and a local injection of corticosteroids in the 
knee was performed. Furthermore, the patient was started on sulfasalacin (2 g/day) for RA. 
After 4 cycles of ipilimumab, melanoma progression was radiologically confirmed in Febru-
ary 2014, and dacarbacin 1,600 mg was given every 3 weeks from April 2014 for a period of 
3 months. In August 2014, the patient underwent treatment with pembrolizumab (2 mg/kg) 
every 3 weeks following recurrent disease progression. The symptoms of RA remained al-
ways under control with no signs of active disease. Nevertheless, the patient died 4 months 
later due to tumor progression.  
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Discussion 
We described a melanoma patient with exacerbation of her RA upon treatment with 
ipilimumab, on the other hand, RA activity was stabilized when she was treated with pem-
brolizumab. RA is considered a CTLA-4+ T helper cell disease. These cells are found in large 
numbers in the synovial milieu in all patients with RA [5]. The exact mechanism by which 
the anti-CTLA drug ipilimumab provokes underlying RA symptoms is still not completely 
understood. CTLA-4 is thought to regulate T-cell proliferation early, whereas PD-1 suppress-
es T cells later in the immune response [6]. The importance of the CTLA-4/CD28 axis for the 
pathologic mechanism of RA has been demonstrated by the successful application of 
abatacept, which is a fusion protein composed of the Fc region of the immunoglobulin IgG1 
linked to the extracellular domain of CTLA-4 [7]. In fact, abatacept prevents the binding of 
CD28:B7 (CD80/86), which blocks the activation of T helper cells [2, 8]. The hypothesis we 
suggest for ipilimumab-induced aggravation of pre-existing RA is that anti-CTLA-4 blocks 
competitively the binding of CTLA-4:B7 (CD80/86) on T helper cells. This can prevent the 
inhibitory signal normally provided by CTLA-4:B7 binding and leads to T-cell activation by 
the CD28-B7 crosstalk and subsequently to increased levels of IFNγ, IL2, and IL-17 in the 
peripheral blood and in the synovial milieu of patients with RA [1, 2]. Although in this case 
ipilimumab appeared to exacerbate RA, a series of previous reports suggest that melanoma 
patients could benefit from ipilimumab without signs of aggravation of any underlying auto-
immune disorders [3, 9, 10].  
This topic is of special importance, since patients with active autoimmune disorders are 
frequently excluded from clinical trials with immunotherapies. Therefore, there is a lack of 
data on how their autoimmune disorders might be affected by immunotherapy.  
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